The PennZone

  • Home
  • Marketing
  • Music
  • Entertainment
  • Non-profit
  • Business
  • Education
  • Technology
  • Event

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
  • Minus K Technology launches it Educational Giveaway for Universities and Colleges in the USA
  • Porter's Day Care Opens Doors to Brighter Futures
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Loud! OOH calls for prize draw advertising standards as £1.3bn category moves outdoors
  • Insurance for Braces Helps Make Treatment More Manageable for Pennsylvania Families
  • Black Ribbon Productions Launches With Fearless 2026 Horror Slate
  • Actor Dominic Pace Returns to Television and Film
  • Opteamix welcomes Girish Ramachandra to its leadership team as Senior Vice President of Client Services

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Kellyn Hosts Fourth Lehigh Valley Lifestyle Medicine Symposium
  • Expanding Beyond Space as New Drone Market Opportunities Accelerate Growth: Ascent Solar Technologies (N A S D A Q: ASTI)
  • Lauren Merrell, Dale Sorensen Real Estate, announces price improvement for an extraordinary island retreat
  • Portalz Publishes FES World First Architecture Introducing a New Cryptographic Platform
  • Racquet Club of Philadelphia appoints Michael J. Sofia as new General Manager
  • Cellofest Brings Free Cello Concerts and Community Events to Bethany Beach August 5–16
  • Blue Sky Capital Strategies, LLC awarded Leasing and Financial Services agreement with Premier Inc
  • Michael M. Thomas Expands Executive Leadership Across Central India Outreach and Royal Trinity School
  • Porter's Day Care Opens Doors to Brighter Futures
  • Northeast Airlines and Travel, Inc. Initiates FAA Part 121 Certification for Boeing 737-800 Freighter Cargo Operations
  • RevOtter Names Levi Bilbrey CEO, as Company Expands Fractional CMO, RevOps and Web Design Services
  • The J Wes Project Announces "The Mystery of Love" Documentary
  • Walker's Realty and North Jersey Properties Introduce Extraordinary Luxury Estate for Rent in West Orange, New Jersey
  • Extreme Heat Strains Home Appliances: Appliance EMT Offers "Summer Rescue" Relief
  • Independent West Texas Metal Multi-Instrumentalist & Producer. "MAD CHAD™" Russell Surpasses 1.9 Million Project Interactions Via DFGS Productions
  • No Download Needed: Goosechase Adds Browser Play to Every Experience
  • HER Patio Productions celebrates one-year Anniversary of "Say Grace"
  • Working Musicians Academy Partners with Black Dog Music Partners to Give Musicians Independent, Income-Producing Careers
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
  • New Research Identifies "The Great Junk Transfer": 49% of Americans Would Rather Inherit Nothing Than Sort Through a Relative's Belongings

Popular on PennZone

  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Community Partnership Brings Live Theater to 150+ Young People
  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Philadelphia Community Invited to Unite for Praise-A-Thon Summer Concert Benefiting Cobbs Creek
  • The J. Wes Project Celebrates 11 Years of Love, Music & Inspiration
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
  • Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers

Similar on PennZone

  • FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us